Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC‑MS/MS combined with iTRAQ technology

Zhang,Peng-Fei; Zeng,Gu-Qing; Yi,Lun-Zhao; Liu,Jian-Ping; Wan,Xun‑Xun; Qu,Jia-Quan; Li,Jian-Huang; Li,Cui; Tang,Can-E; Hu,Rong; Ye,Xu; Chen,Yu; Chen,Zhu-Chu; Xiao,Zhi-Qiang

doi:10.3892/or.2013.2477

Identification of integrin β1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC‑MS/MS combined with iTRAQ technology

Authors:
- Peng-Fei Zhang
- Gu-Qing Zeng
- Lun-Zhao Yi
- Jian-Ping Liu
- Xun‑Xun Wan
- Jia-Quan Qu
- Jian-Huang Li
- Cui Li
- Can-E Tang
- Rong Hu
- Xu Ye
- Yu Chen
- Zhu-Chu Chen
- Zhi-Qiang Xiao
View Affiliations

Affiliations: Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: May 15, 2013 https://doi.org/10.3892/or.2013.2477
Pages: 341-349

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To discover novel lung adenocarcinoma (AdC) biomarkers, isobaric tags for relative and absolute quantitation (iTRAQ)-tagging combined with 2D-LC-MS/MS analysis was used to identify differentially expressed plasma membrane proteins in lung AdC and paired paraneoplastic normal lung tissues (PNLTs) adjacent to tumors. In this study, significant caveolin-1 downregulation and integrin β1 upregulation was observed in primary lung AdC vs. PNLT. As there has been no report on the association of integrin β1 with lung AdC, immunohistochemical staining was performed to detect the expression of integrin β1 in an independent set of archival tissue specimens including 42 cases of PLNT, 46 cases of without lymph node metastasis primary AdC (non-LNM AdC) and 62 cases of LNM AdC; the correlation of their expression levels with clinicopathological characteristics and clinical outcomes were evaluated. Based on the data, upregulation of integrin β1 was significantly correlated with advanced clinical stage and lymph node metastasis. Integrin β1 overexpression was significantly associated with advanced clinical stage (P<0.05), lymph node metastasis (P<0.05), increased relapse rate (P<0.05) and decreased overall survival (P<0.05) in AdCs. Cox regression analysis indicated that integrin β1 overexpression is an independent prognostic factor. The data suggest that integrin β1 is a potential biomarker for LNM and prognosis of AdC and integrin β1 upregulation may play an important role in the pathogenesis of AdC.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Yang L, Parkin DM, Li LD, Chen YD and Bray F: Estimation and projection of the national profile of cancer mortality in China: 1991–2005. Br J Cancer. 90:2157–2166. 2004.PubMed/NCBI
3	Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG and Edwards BK: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 93:824–842. 2001. View Article : Google Scholar : PubMed/NCBI
4	Little AG, Gay EG, Gaspar LE and Stewart AK: National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer. 57:253–260. 2007. View Article : Google Scholar : PubMed/NCBI
5	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
6	Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA and Sobel ME: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 80:200–204. 1988. View Article : Google Scholar : PubMed/NCBI
7	Chen JJ, Peck K, Hong TM, Yang SC, Sher YP, Shih JY, Wu R, et al: Global analysis of gene expression in invasion by a lung cancer model. Cancer Res. 61:5223–5230. 2001.PubMed/NCBI
8	Nakamura N, Kobayashi K, Nakamoto M, Kohno T, Sasaki H, Matsuno Y and Yokota J: Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene. 25:4245–4255. 2006. View Article : Google Scholar : PubMed/NCBI
9	Tian T, Hao J, Xu A, Hao J, Luo C, Liu C, Huang L, Xiao X and He D: Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci. 98:1265–1274. 2007. View Article : Google Scholar : PubMed/NCBI
10	Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, et al: Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 8:2298–2305. 2002.PubMed/NCBI
11	Chen G, Gharib TG, Thomas DG, Huang CC, Misek DE, Kuick RD, Giordano TJ, et al: Proteomic analysis of eIF-5A in lung adenocarcinomas. Proteomics. 3:496–504. 2003. View Article : Google Scholar : PubMed/NCBI
12	Rho JH, Roehrl MH and Wang JY: Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res. 8:5610–5618. 2009. View Article : Google Scholar : PubMed/NCBI
13	Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, Li F, et al: Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 217:54–64. 2009. View Article : Google Scholar : PubMed/NCBI
14	Liu YF, Zhang PF, Li MY, Li QQ and Chen ZC: Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma. Clin Exp Metastasis. 28:413–425. 2011. View Article : Google Scholar : PubMed/NCBI
15	Emmott E, Wise H, Loucaides EM, Matthews DA, Digard P and Hiscox JA: Quantitative proteomics using SILAC coupled to LC-MS/MS reveals changes in the nucleolar proteome in influenza A virus-infected cells. J Proteome Res. 9:5335–5345. 2010. View Article : Google Scholar : PubMed/NCBI
16	Qattan AT, Mulvey C, Crawford M, Natale DA and Godovac-Zimmermann J: Quantitative organelle proteomics of MCF-7 breast cancer cells reveals multiple subcellular locations for proteins in cellular functional processes. J Proteome Res. 9:495–508. 2010. View Article : Google Scholar
17	Wu CC, MacCoss MJ, Howell KE and Yates JR III: A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol. 21:532–538. 2003. View Article : Google Scholar : PubMed/NCBI
18	Wu CC and Yates JR III: The application of mass spectrometry to membrane proteomics. Nat Biotechnol. 21:262–267. 2003. View Article : Google Scholar : PubMed/NCBI
19	Dowling P, Meleady P, Dowd A, Henry M, Glynn S and Clynes M: Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim Biophys Acta. 1774:93–101. 2007. View Article : Google Scholar : PubMed/NCBI
20	Liang X, Zhao J, Hajivandi M, Wu R, Tao J, Amshey JW and Pope RM: Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. J Proteome Res. 5:2632–2641. 2006. View Article : Google Scholar : PubMed/NCBI
21	Stockwin LH, Blonder J, Bumke MA, Lucas DA, Chan KC, Conrads TP, Issaq HJ, et al: Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J Proteome Res. 5:2996–3007. 2006. View Article : Google Scholar : PubMed/NCBI
22	Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
23	Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE and Schnitzer JE: Subtractive proteomic mapping of the endothelial surface in lung and solid tumors for tissue-specific therapy. Nature. 429:629–635. 2004. View Article : Google Scholar : PubMed/NCBI
24	Cao R, Li X, Liu Z, Peng X, Hu W, Wang X, Chen P, et al: Integration of a two-phase partition method into proteomics research on rat liver plasma membrane proteins. J Proteome Res. 5:634–642. 2006. View Article : Google Scholar : PubMed/NCBI
25	Xiao Z, Li G, Chen Y, Li M, Peng F, Li C, Li F, et al: Quantitative proteomic analysis of formalin-fixed and paraffin-embedded nasopharyngeal carcinoma using iTRAQ labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. J Histochem Cytochem. 58:517–527. 2010. View Article : Google Scholar
26	Krogh A, Larsson B, von Heijne G and Sonnhammer EL: Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol. 305:567–580. 2001. View Article : Google Scholar : PubMed/NCBI
27	Kyte J and Doolittle RF: A simple method for displaying the hydropathic character of a protein. J Mol Biol. 157:105–132. 1982. View Article : Google Scholar : PubMed/NCBI
28	Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, et al: Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res. 14:435–445. 2008. View Article : Google Scholar : PubMed/NCBI
29	Tarone G, Hirsch E, Brancaccio M, De Acetis M, Barberis L, Balzac F, Retta SF, et al: Integrin function and regulation in development. Int J Dev Biol. 44:725–731. 2000.PubMed/NCBI
30	Hollenbeck ST, Itoh H, Louie O, Faries PL, Liu B and Kent KC: Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60^src-dependent crosstalk between the α2β1 integrin and PDGFβ receptor. Biochem Biophys Res Commun. 325:328–337. 2004. View Article : Google Scholar : PubMed/NCBI
31	Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G and Defilippi P: Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 17:6622–6632. 1998. View Article : Google Scholar : PubMed/NCBI
32	Bhowmick NA, Zent R, Ghiassi M, McDonnell M and Moses HL: Integrin β1 signaling is necessary for transforming growth factor-β activation of p38MAPK and epithelial plasticity. J Biol Chem. 276:46707–46713. 2001.
33	Frish SM and Francis H: Disruption of epithelial cell-matrix interaction induces apoptosis. J Cell Biol. 124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI
34	Aoudjit F and Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 20:4995–5004. 2001. View Article : Google Scholar : PubMed/NCBI
35	Yamada KM, Kennedy DW, Yamada SS, Gralnick H, Chen WT and Akiyama SK: Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration. Cancer Res. 50:4485–4496. 1990.PubMed/NCBI
36	Bredin CG, Sundqvist KG, Hauzenberger D and Klominek J: Integrin dependent migration of lung cancer cells to extracellular matrix components. Eur Respir J. 11:400–407. 1998. View Article : Google Scholar : PubMed/NCBI
37	Ju LX, Zhou CC, Li W and Yan LH: Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lungcancer. J Cell Biochem. 111:1565–1574. 2010. View Article : Google Scholar : PubMed/NCBI
38	Zhao G, Cui J, Qin Q, Zhang J, Liu L, Deng S, Wu C, et al: Mechanical stiffness of liver tissues in relation to integrin β1 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma. J Surg Oncol. 102:482–489. 2010.PubMed/NCBI
39	Oshita F, Kameda Y, Ikehara M, Tanaka G, Yamada K, et al: Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. 22:1065–1070. 2002.PubMed/NCBI
40	Chang MH, Lee K, Lee KY, Kim YS, Kim YK and Kang JH: Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer. APMIS. 120:28–38. 2012.